Puma Biotechnology (PBYI) Stock Rating Lowered by Barclays

Puma Biotechnology (NASDAQ:PBYI) was downgraded by equities researchers at Barclays from an “overweight” rating to an “equal weight” rating in a report released on Thursday, MarketBeat.com reports. They presently have a $90.00 price objective on the biopharmaceutical company’s stock. Barclays’ price target points to a potential upside of 35.54% from the stock’s previous close.

A number of other equities analysts have also issued reports on the company. Credit Suisse Group set a $142.00 price target on Puma Biotechnology and gave the stock a “buy” rating in a report on Monday, January 15th. Zacks Investment Research raised Puma Biotechnology from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Citigroup reissued a “buy” rating and set a $164.00 price target on shares of Puma Biotechnology in a report on Wednesday, January 3rd. BidaskClub upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research report on Saturday, February 17th. Finally, ValuEngine downgraded shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the company’s stock. Puma Biotechnology has an average rating of “Hold” and an average target price of $103.11.

NASDAQ PBYI opened at $66.40 on Thursday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.79 and a current ratio of 1.82. Puma Biotechnology has a 52-week low of $28.35 and a 52-week high of $136.90. The stock has a market cap of $2,495.16, a P/E ratio of -8.46 and a beta of 0.15.



Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.27. The company had revenue of $21.60 million for the quarter, compared to analysts’ expectations of $20.83 million. During the same period in the prior year, the business earned ($1.22) EPS. analysts predict that Puma Biotechnology will post -4.07 earnings per share for the current fiscal year.

In related news, SVP Richard Paul Bryce sold 1,860 shares of the firm’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $92.75, for a total value of $172,515.00. Following the completion of the sale, the senior vice president now owns 25,379 shares in the company, valued at $2,353,902.25. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Alan H. Auerbach sold 10,692 shares of the firm’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $92.75, for a total transaction of $991,683.00. Following the completion of the sale, the insider now owns 4,155,931 shares of the company’s stock, valued at approximately $385,462,600.25. The disclosure for this sale can be found here. 21.10% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in the stock. First Republic Investment Management Inc. acquired a new stake in shares of Puma Biotechnology during the 4th quarter valued at approximately $208,000. Sei Investments Co. acquired a new stake in shares of Puma Biotechnology during the 3rd quarter valued at approximately $256,000. Jafra Capital Management LP acquired a new stake in shares of Puma Biotechnology during the 4th quarter valued at approximately $257,000. Clear Harbor Asset Management LLC acquired a new stake in shares of Puma Biotechnology during the 4th quarter valued at approximately $288,000. Finally, Xact Kapitalforvaltning AB acquired a new stake in shares of Puma Biotechnology during the 4th quarter valued at approximately $292,000. Hedge funds and other institutional investors own 95.95% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Puma Biotechnology (PBYI) Stock Rating Lowered by Barclays” was originally published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/14/puma-biotechnology-pbyi-stock-rating-lowered-by-barclays.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply